abstract |
The present invention relates to an antibody, an immunoglobulin construct or an immunoglobulin IgG4 fusion protein, wherein its in vivo half-lives are (i) modified IgG4 Fc region or its FcRn Binding domain and (ii) modified IgG4 hinge region sequence. |